




The relative strengths and weaknesses of Acadia Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acadia Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Acadia Pharmaceuticals INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 346%, being 96% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	526,106
Cost of Goods Sold	0
Intangible Assets	4,062
Liabilities, Current	59,565
Liabilities, Non-Current	1,558
Other Assets	6,725
Other Compr. Net Income	27
Other Expenses	21,426
Other Liabilities	0
Other Net Income	5,348
Other Revenues	223,807
Property and Equipment	3,309
Research and Development	187,163
Selling, General and Administrative Expense	265,758

Output Variable	Value in 1000 USD
Assets	540,202
Liabilities	61,123
Expenses	474,347
Revenues	223,807
Stockholders Equity	479,079
Net Income	-245,192
Comprehensive Net Income	-245,178
BaseVar	652,427
ECR before Limited Liability	266%
Economic Capital Ratio	346%